A single bacterial species could amplify the entire pathological process
For decades, clinicians puzzled over why two patients with the same hormonal disorder could face such different fates for their bones. A research team led by Professor Roberto Pacifici has found part of the answer not in the skeleton or the blood, but in the gut — where specific bacterial species quietly shape the immune responses that determine how much bone a person loses. The discovery that a single microbe, Bifidobacterium longum, can amplify inflammatory pathways and accelerate skeletal damage reframes primary hyperparathyroidism as a disease with an invisible co-author, and opens the possibility that the gut microbiome may one day be read as a map of individual risk.
- Two patients with nearly identical hormone levels can have vastly different rates of bone loss — a clinical mystery that has gone unexplained for years.
- Fecal transplant experiments in germ-free mice proved the microbiome is not merely a bystander: bacteria from osteoporotic patients directly caused greater bone loss in animals that received them.
- A single species, Bifidobacterium longum, drives the damage by expanding inflammatory TNF-producing T cells and Th17 cells that migrate from the gut to bone tissue and accelerate mineral breakdown.
- The critical difference between patients was not broad shifts in microbial diversity but the abundance of specific bacteria — a precision that makes targeted intervention feel newly plausible.
- Researchers now envision microbiome-based biomarkers to flag high-risk patients early, and precision probiotics or selective bacterial modulation as potential therapies alongside existing hormonal treatments.
Primary hyperparathyroidism has long seemed like a disease with a simple logic: overactive parathyroid glands raise calcium, and bones weaken. Yet clinicians have always noticed an unsettling inconsistency — two patients with nearly identical hormone levels can diverge sharply, one losing bone rapidly while the other's skeleton holds. Professor Roberto Pacifici's team decided to look for the explanation in an unlikely place: the gut.
The researchers collected stool samples from fifty hyperparathyroid patients, measured their bone density, and profiled their immune cells. A clear pattern emerged — the bacterial composition of the intestine correlated directly with the degree of bone loss. To move beyond correlation, they transplanted stool from patients with severe osteoporosis, mild bone loss, and normal bone density into germ-free mice. The outcome was unambiguous: mice colonized with bacteria from osteoporotic patients lost significantly more bone. The microbiome was a cause, not a coincidence.
The mechanism ran through the immune system. Two inflammatory cell types — TNF-producing T cells and Th17 cells — were consistently elevated in patients with severe bone loss and in the mice that received their bacteria. These cells appeared to be the bridge between gut bacteria and skeletal damage. Among all the species examined, one stood out: Bifidobacterium longum. Its abundance predicted higher levels of the inflammatory molecules TNF and IL-17, and in mice colonized with it, these immune cells expanded in the gut and bone marrow before migrating to bone tissue and accelerating its breakdown.
Strikingly, the difference between patients was not found in broad patterns of microbial diversity — the overall landscape of bacteria looked similar across groups. The divergence came down to the abundance of specific species, a specificity that carries real clinical weight. If a handful of bacteria determine who faces severe complications, stool analysis could become a tool for identifying high-risk patients before significant damage occurs.
The findings also point toward new treatment strategies. Rather than focusing solely on hormone and calcium management, clinicians might one day target Bifidobacterium longum directly — through precision probiotics, selective antibiotics, or other microbiota-directed approaches — tailoring care to each patient's microbial profile. A disease once thought to follow a single trajectory now appears to branch, guided in part by the invisible ecosystem living in the gut.
Primary hyperparathyroidism is a straightforward disease: the parathyroid glands overproduce hormone, calcium levels rise, and bones begin to weaken. Yet something strange happens in the clinic. Two patients with nearly identical hormone levels can have vastly different outcomes. One loses bone rapidly and faces fracture risk. The other's skeleton remains largely intact. For years, doctors had no explanation for this divergence.
A team led by Professor Roberto Pacifici set out to solve the puzzle by looking somewhere unexpected: the gut. They collected stool samples from fifty people with primary hyperparathyroidism, measured their bone density, and profiled their immune cells. What emerged was a clear pattern. The composition of bacteria living in their intestines correlated directly with how much bone they were losing. But correlation is not proof. To establish that the microbiome was actually causing the bone loss—not merely accompanying it—the researchers performed a striking experiment. They took stool samples from hyperparathyroid patients with severe osteoporosis, mild bone loss, and normal bone density, then transplanted those bacterial communities into germ-free mice that had never been colonized by any microbes. The results were unambiguous. Mice that received bacteria from osteoporotic patients developed greater bone loss than those receiving bacteria from patients with healthy bones. The microbiome was not just a bystander.
The mechanism emerged through careful detective work. Two types of immune cells stood out: T cells that produce tumor necrosis factor, or TNF, and a subset called Th17 cells. Both are inflammatory. Both were consistently elevated in patients with severe bone loss and in the mice that had received their bacteria. Higher levels of these cells correlated with lower bone density. The immune system, it seemed, was the bridge between gut bacteria and skeletal damage.
Among dozens of bacterial species, one rose to prominence: Bifidobacterium longum. When researchers measured its abundance in patient samples, they found a clear relationship. More of this bacterium meant higher levels of TNF and another inflammatory molecule called IL-17, both known to accelerate bone breakdown. In mice colonized with Bifidobacterium longum, these immune cells expanded in the intestine and bone marrow, then migrated to bone tissue where they released factors that dissolved bone mineral. When those mice were exposed to elevated parathyroid hormone—mimicking the human disease—they lost bone far more rapidly than controls. A single bacterial species could amplify the entire pathological process.
What made this finding particularly striking was what the researchers did not find. Overall microbiome diversity and composition looked similar across patients with severe bone loss, mild bone loss, and normal bones. The difference was not in the forest but in a single tree. Susceptibility to bone loss depended on the abundance of specific bacterial species, not broad shifts in the microbial community. This specificity opens a door. If a handful of bacteria determine who suffers severe complications, then identifying those bacteria in a patient's stool could predict risk. Microbiome-based biomarkers might tell a doctor which hyperparathyroid patients need aggressive monitoring or intervention.
The findings also suggest new treatment paths. Current approaches focus on managing hormone levels and calcium balance. But if Bifidobacterium longum is driving immune activation and bone loss, then targeting that bacterium—through selective antibiotics, precision probiotics designed to outcompete it, or other microbiota-directed strategies—might prevent or reduce skeletal damage. Such interventions could work alongside existing therapies, tailored to each patient's microbial profile. The disease that once seemed to follow a single path now appears to have multiple routes, each determined partly by the invisible ecosystem living in the gut.
Citações Notáveis
The extent to which primary hyperparathyroidism impacts the skeleton correlated with the abundance of Bifidobacterium longum, a bacterium that induces expansion of inflammatory T cells and Th17 cells.— Professor Roberto Pacifici
The presence of Bifidobacterium longum in the gut microbiome allows PTH to cause the expansion and migration of TNF+ T cells and Th17 cells and to induce bone loss.— Professor Roberto Pacifici
A Conversa do Hearth Outra perspectiva sobre a história
Why does this matter? Hyperparathyroidism is already a known disease. Doctors can measure hormone levels and prescribe treatment.
They can manage the hormone, yes. But they can't predict who will lose bone and who won't. Two patients with identical PTH levels can have completely different outcomes. One fractures easily; the other's skeleton holds. This research explains why—and that's the difference between treating a disease blindly and treating it with precision.
So you're saying the bacteria are the real culprit, not the hormone?
Not exactly. The hormone is still the underlying problem. But Bifidobacterium longum acts as an amplifier. Without it, the hormone does less damage. With it, the same hormone level causes much more bone loss. It's like the bacteria are turning up the volume on the disease.
How did they prove the bacteria were actually causing it, not just present when bone loss happens?
They transplanted bacteria from sick patients into mice that had never had any bacteria at all. The mice developed bone loss. That's causation. You can't argue with that kind of experiment.
What happens next? Can doctors test for this bacterium?
That's the hope. If a simple stool test could identify which patients carry high levels of Bifidobacterium longum, doctors could flag them as high-risk and intervene earlier. Or they could try to reduce the bacterium before bone loss becomes severe.
With antibiotics?
Possibly, though broad antibiotics would kill everything. The real promise is in precision approaches—probiotics designed to outcompete this specific bacterium, or targeted interventions that only affect it. That's still years away, but the science now points in that direction.